The redirection of the thematic areas at the AECOM CFAR to immune-based therapeutic and preventive agendas has mandated in 1990 the conversion of the original hybridoma core into an immunology/vaccine core. This new core standardizes a wide array of immunology markers in the context of antiviral and immune based interventions targeted at manifestation of host defense mechanisms in order to prevent infection or improve outcome. The core will provide access to otherwise unobtainable research capabilities in two major categories critical for the CFAR's progress: (a) Immunological surrogate markers, such as neopterin, Beta2, TNFalpha, sCD8. (b) HIV specific assays targeted to variety of epitopes, but currently focused on gp120 and in the V3 loop primary neutralizing domain (PND) (i) Humoral immune response: serum and secretory IgA (purified at the core) will be assessed for PND reactivity, PND high affinity/avidity cross reactivity; PND and IgG-subclass specific antibodies. (ii) Cellular immunity: Antigen (PND;gp120) driven lymphocyte proliferation, secretion of IL2;IL4;IL10; and specific CTLs of PBMC and sorted cells. This core will be highly interactive with other cores, but more so with the FACS and virology cores. The Core Director will continuously assess the needs for incorporation of new promising immunological assays critical in advancing the common goals of the CFAR and the AECOM-AIDS research agenda. He will be responsible to keep CFAR investigators abreast of new developments in core capabilities and enrich those by interaction with the CFAR committees, the EAC and through visiting scientists/consultants.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Albert Einstein College of Medicine
United States
Zip Code
Rubinstein, Arye (2005) Preclinical studies of alkylureas as anti-HIV-1 contraceptive. Curr Pharm Des 11:3769-78
Lenz, J; Su, M; Mizrachi, Y et al. (2001) V3 variation in HIV-seropositive patients receiving a V3- targeted vaccine. AIDS 15:577-81
Browning Paul, J; Wang, E J; Pettoello-Mantovani, M et al. (2000) Mice transgenic for monocyte-tropic HIV type 1 produce infectious virus and display plasma viremia: a new in vivo system for studying the postintegration phase of HIV replication. AIDS Res Hum Retroviruses 16:481-92
Rubinstein, A; Mizrachi, Y; Bernstein, L et al. (2000) Progressive specific immune attrition after primary, secondary and tertiary immunizations with bacteriophage phi X174 in asymptomatic HIV-1 infected patients. AIDS 14:F55-62
Yurasov, S V; Pettoello-Mantovani, M; Raker, C A et al. (1999) HIV type 1 infection of human fetal bone marrow cells induces apoptotic changes in hematopoietic precursor cells and suppresses their in vitro differentiation and capacity to engraft SCID mice. AIDS Res Hum Retroviruses 15:1639-52
Rubinstein, A; Mizrachi, Y; Pettoello-Mantovani, M et al. (1999) Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates. J Acquir Immune Defic Syndr 22:467-76
Pettoello-Mantovani, M; Kollmann, T R; Katopodis, N F et al. (1998) thy/liv-SCID-hu mice: a system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues. J Infect Dis 177:337-46
Landor, M; Rubinstein, A; Kim, A et al. (1998) Receptor-mediated maternofetal transfer of immunoglobulins. Inhibition of transport of anti-HIV-1 immunoglobulin by generic immunoglobulins in the in vitro perfused placenta. Int Arch Allergy Immunol 115:203-9
Browning, J; Horner, J W; Pettoello-Mantovani, M et al. (1997) Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc Natl Acad Sci U S A 94:14637-41
Harish, Z; Rubinstein, A; Golodner, M et al. (1997) Suppression of HIV-1 replication by propolis and its immunoregulatory effect. Drugs Exp Clin Res 23:89-96

Showing the most recent 10 out of 36 publications